Literature DB >> 3995681

Prevention of cyclophosphamide-induced urotoxicity by reduced glutathione and its effect on acute toxicity and antitumor activity of the alkylating agent.

O Tofanetti, E Cavalletti, A Besati, G Pratesi, G Pezzoni, F Zunino.   

Abstract

The effect of reduced glutathione on acute lethal toxicity and urotoxicity induced by cyclophosphamide was studied on both mice and rats. The results of this investigation indicate that reduced glutathione is an effective protective agent against bladder damage from treatment with the alkylating agent. The timing of glutathione administration (IV) with respect to cyclophosphamide treatment influenced the uroprotective efficacy of the thiol compound. A schedule-dependent protective effect of glutathione against acute lethal toxicity of the antitumor drug was also observed. This partial protection was accompanied by a reduction in body weight loss following cyclophosphamide treatment. The therapeutic activity of cyclophosphamide on two experimental tumor systems (L1210 and Gross leukemia) was not impaired by combined treatment with glutathione, even at a relatively high dose of glutathione compared with cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3995681     DOI: 10.1007/bf00258114

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

1.  The fate of extracellular glutathione in the rat.

Authors:  R Hahn; A Wendel; L Flohé
Journal:  Biochim Biophys Acta       Date:  1978-03-20

Review 2.  Protection against the toxicity of alkylating agents by thiols: the mechanism of protection and its relevance to cancer chemotherapy. A review.

Authors:  T A Connors
Journal:  Eur J Cancer       Date:  1966-12       Impact factor: 9.162

3.  Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.

Authors:  N Brock; J Pohl; J Stekar
Journal:  Eur J Cancer Clin Oncol       Date:  1981-11

4.  High-dose cyclophosphamide (7 g/m2) with or without autologous bone marrow rescue after conventional chemotherapy in the treatment of patients with small cell lung cancer.

Authors:  I E Smith; B D Evans; S J Harland
Journal:  Cancer Treat Rev       Date:  1983-09       Impact factor: 12.111

Review 5.  Ifosfamide in experimental tumor systems.

Authors:  A Goldin
Journal:  Semin Oncol       Date:  1982-12       Impact factor: 4.929

Review 6.  The comparative pharmacology of cyclophosphamide and ifosfamide.

Authors:  M Colvin
Journal:  Semin Oncol       Date:  1982-12       Impact factor: 4.929

Review 7.  The role of nonenzymatic reactions of glutathione in xenobiotic metabolism.

Authors:  B Ketterer
Journal:  Drug Metab Rev       Date:  1982       Impact factor: 4.518

8.  Transport of glutathione, as gamma-glutamylcysteinylglycyl ester, into liver and kidney.

Authors:  R N Puri; A Meister
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

9.  Effect of disulfiram (tetraethylthiuram disulfide) amd diethyldithiocarbamate on the bladder toxicity and antitumor activity of cyclophosphamide in mice.

Authors:  M P Hacker; W B Ershler; R A Newman; R L Gamelli
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

10.  Role of glutathione in the metabolism-dependent toxicity and chemotherapy of cyclophosphamide.

Authors:  H L Gurtoo; J H Hipkens; S D Sharma
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

View more
  4 in total

1.  Intravenous glutathione prevents renal oxidative stress after coronary angiography more effectively than oral N-acetylcysteine.

Authors:  Takeji Saitoh; Hiroshi Satoh; Mamoru Nobuhara; Masashi Machii; Takamitsu Tanaka; Hayato Ohtani; Masao Saotome; Tsuyoshi Urushida; Hideki Katoh; Hideharu Hayashi
Journal:  Heart Vessels       Date:  2010-12-03       Impact factor: 2.037

2.  Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells.

Authors:  R H Peters; K Ballard; J E Oatis; D J Jollow; R K Stuart
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  L-cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity.

Authors:  J C Roberts; D J Francetic; R T Zera
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  Weekly 5-fluorouracil and folinic acid plus escalating doses of cisplatin with glutathione protection in patients with advanced head and neck cancer.

Authors:  V Gebbia; R Valenza; A Testa; G Zerillo; S Restivo; G Cupido; F Ingria; G Spadafora; C Barbaccia; G Cannata
Journal:  Med Oncol Tumor Pharmacother       Date:  1992
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.